emjreviews.com12h
New Strategy Enhances PD-1 Therapy in Treatment-Resistant Cancers
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Pharmabiz1d
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
The American Journal of Managed Care4d
2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...
Medscape20h
Bladder Cancer Survival Better With Nivolumab Than Placebo in New Analysis
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Medpage Today on MSN5mon
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
He also cautioned that pembrolizumab may not be a relevant comparator for the intermediate PD-L1 population (PD-L1 tumor ...
precisionmedicineonline1d
Cel-Sci to Initiate Phase III Trial of Immunotherapy in PD-L1-Low Head and Neck Cancer
The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.
BioWorld2d
BA-4415, an anti-PD-L1/CD40 bispecific antibody for cancer immunotherapy
Researchers from Tianjin University have published data regarding development and preclinical characterization of a new anti-PD-L1/CD40 bispecific antibody (BsAb), BA-4415, designed to activate CD40 ...
emjreviews.com18h
Enhancing Immunotherapy by Targeting Specific Receptors in Ovarian Cancer
Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.
Targeted Oncology4d
Brahmer Considers First-Line Immunotherapy Options in Metastatic NSCLC
During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
SCI Corporation (NYSE American: CVM) today reported financial results for three months ended December 31, 2024, as well as ...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...